We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TRD

News List

Denovo Biopharma LLC Announces FDA Approval of IND to Initiate First Biomarker-Guided Global CNS Clinical Trial for Treatment-Resistant Depression (TRD) prnasia
February 07, 2022
Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced that the FDA has authorized the company's investigational new drug (IND) application...
Training begins for psychedelic-assisted clinical trial pharmatimes
January 24, 2022
Beckley Psytech leads a new project focused on addressing psychiatric and neurological conditions through the use of psychedelic medicines.
New data highlights value of Janssen’s Spravato pharmatimes
May 29, 2019
New data has illustrated the value of Janssen’s oral antidepressant Spravato (esketamine) CIII nasal spray for treatment-resistant depression (TRD).
FDA approves Janssen’s ketamine-based nasal antidepressant pharmaphorum
March 07, 2019
The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to specialist clinics.